<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585558</url>
  </required_header>
  <id_info>
    <org_study_id>15-50310X</org_study_id>
    <nct_id>NCT01585558</nct_id>
  </id_info>
  <brief_title>Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus</brief_title>
  <official_title>Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus: A 40 Week Randomized, Double Blind, Placebo Controlled, Follow-Up to Protocol 15-50310.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>QuatRx Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shionogi Inc.</source>
  <brief_summary>
    <textblock>
      The primary objective of the study was to assess the long-term safety of 30- and 60-mg daily
      doses of ospemifene in the treatment of Vulvar and Vaginal Atrophy (VVA) in postmenopausal
      women with an intact uterus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2006</start_date>
  <completion_date type="Actual">September 18, 2008</completion_date>
  <primary_completion_date type="Actual">August 19, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Week 20 (Phone Contact) to Week 56 (Visit 7)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Cervical Pap Smear Samples</measure>
    <time_frame>Week 52 (Visit 6)</time_frame>
    <description>Cervical Pap smear samples were used to evaluate: atypical squamous cells of undetermined significance (ASC-US), squamous intraepithelial lesions (SILs), intraepithelial lesions or malignancy, and reactive endocervical cells and/or metaplastic cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Endometrial Biopsy</measure>
    <time_frame>Week 52 (Visit 6)</time_frame>
    <description>Assessments were based on Blaustein's classification.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline in Serum Lipids</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline in Serum Lipids</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Blood Chemistry Parameters</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Blood Chemistry Parameters</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Endometrial Safety With a Transvaginal Ultrasound (TVU)</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
    <description>Mean change in endometrial thickness from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Endometrial Safety With a TVU</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
    <description>Mean change in endometrial thickness from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Visual Evaluation of the Vagina</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
    <description>Petechiae, pallor, friability, dryness in the mucosa, and redness in the mucosa were assessed on a 4-point scale (0=None, 1=Mild, 2=Moderate, 3=Severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Visual Evaluation of the Vagina</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
    <description>Petechiae, pallor, friability, dryness in the mucosa, and redness in the mucosa were assessed on a 4-point scale (0=None, 1=Mild, 2=Moderate, 3=Severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Estradiol (E2) Levels</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Luteinizing Hormone (LH) Levels</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Follicle Stimulating Hormone (FSH) Levels</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Sex Hormone Binding Globulin (SHBG) Levels</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Testosterone (Total) Levels</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Testosterone (Free) Levels</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in E2 Levels</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in LH Levels</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in FSH Levels</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in SHBG Levels</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Mammography</measure>
    <time_frame>Week 52 (Visit 6)</time_frame>
    <description>Mammography was done for the detection of characteristic masses and microcalcifications in the breast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Testosterone (Total) Levels</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Testosterone (Free) Levels</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Antithrombin Antigen, P Levels</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Fibrinogen Levels</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Protein C Ag, P Levels</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Protein S Ag (Free), P Levels</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Thromboplastin Time</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Antithrombin Antigen, P Levels</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Fibrinogen Levels</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Protein C Ag, P Levels</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Protein S Ag (Free), P Levels</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Thromboplastin Time</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Breast Palpation</measure>
    <time_frame>Week 26 (Visit 5)</time_frame>
    <description>Breast palpation was done by the investigator to assess abnormalities in the breast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Breast Palpation</measure>
    <time_frame>Week 52 (Visit 6)</time_frame>
    <description>Breast palpation was done by the investigator to assess abnormalities in the breast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Hematology Tests</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Erythrocyte (RBC) Levels</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hemogobin Levels</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematocrit Levels</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Hematology Test Values</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Erythrocyte (RBC) Levels</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin Levels</measure>
    <time_frame>Baseine to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematocrit Levels</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in pH of Urine</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Specific Gravtiy of Urine</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in pH of Urine</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Specific Gravity of Urine</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Pulse Rate</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Weight</measure>
    <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in BMI</measure>
    <time_frame>Baseline to Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in SBP</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in DBP</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Pulse Rate</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Weight</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in BMI</measure>
    <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Atrophy</condition>
  <condition>Vaginal Diseases</condition>
  <arm_group>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ospemifene (Dose 1)</intervention_name>
    <arm_group_label>Treatment Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ospemifene (Dose 2)</intervention_name>
    <arm_group_label>Treatment Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Treatment Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women aged 40 to 80 years with a diagnosis of vulvar and vaginal
             atrophy (VVA) as assessed by vaginal pH, maturation index of vaginal smear, and
             self-reported symptoms at Baseline for Protocol 15-50310

          -  Had an intact uterus

          -  Met the inclusion and exclusion criteria for Protocol 15-50310

          -  Had completed Protocol 15-50310

        Exclusion Criteria:

          -  Had clinically significant abnormal findings at the Week 12 End of Study visit for
             Protocol 15-50310

          -  Had any physical or mental condition which, in the opinion of the investigator, may
             have interfered with the subject's ability to comply with the study procedures
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2012</study_first_submitted>
  <study_first_submitted_qc>April 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <results_first_submitted>March 20, 2013</results_first_submitted>
  <results_first_submitted_qc>May 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 28, 2013</results_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menopausal symptoms</keyword>
  <keyword>Urogenital atrophy</keyword>
  <keyword>Vulvar and vaginal atrophy in menopausal women</keyword>
  <keyword>Vaginal atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ospemifene 30 mg (Dose 1)</title>
          <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
        </group>
        <group group_id="P2">
          <title>Ospemifene 60 mg (Dose 2)</title>
          <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ospemifene 30 mg (Dose 1)</title>
          <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
        </group>
        <group group_id="B2">
          <title>Ospemifene 60 mg (Dose 2)</title>
          <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="180"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.4" spread="6.13"/>
                    <measurement group_id="B2" value="57.7" spread="5.88"/>
                    <measurement group_id="B3" value="58.2" spread="4.02"/>
                    <measurement group_id="B4" value="58.1" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="174"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162.83" spread="6.930"/>
                    <measurement group_id="B2" value="162.53" spread="6.488"/>
                    <measurement group_id="B3" value="163.27" spread="6.082"/>
                    <measurement group_id="B4" value="162.84" spread="6.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.92" spread="11.316"/>
                    <measurement group_id="B2" value="65.52" spread="11.626"/>
                    <measurement group_id="B3" value="66.71" spread="10.482"/>
                    <measurement group_id="B4" value="67.02" spread="11.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.014" spread="4.1507"/>
                    <measurement group_id="B2" value="24.792" spread="4.1292"/>
                    <measurement group_id="B3" value="25.045" spread="3.8496"/>
                    <measurement group_id="B4" value="25.282" spread="4.0762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events (AEs)</title>
        <time_frame>Week 20 (Phone Contact) to Week 56 (Visit 7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events (AEs)</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment-Emergent AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE (Possibly/Probably/Definitely Related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Causing Study Drug Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Cervical Pap Smear Samples</title>
        <description>Cervical Pap smear samples were used to evaluate: atypical squamous cells of undetermined significance (ASC-US), squamous intraepithelial lesions (SILs), intraepithelial lesions or malignancy, and reactive endocervical cells and/or metaplastic cells.</description>
        <time_frame>Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 34 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Cervical Pap Smear Samples</title>
          <description>Cervical Pap smear samples were used to evaluate: atypical squamous cells of undetermined significance (ASC-US), squamous intraepithelial lesions (SILs), intraepithelial lesions or malignancy, and reactive endocervical cells and/or metaplastic cells.</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 34 out of 49 subjects in the placebo group were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ASC-US</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inadequate squamous epithelial component</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low grade SIL (slight dysplasia and/or HPV effect)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative for intraepithelial lesion or malignancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reactive endocervical and/or metaplastic cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsatisfactory: Due to reasons noted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Endometrial Biopsy</title>
        <description>Assessments were based on Blaustein’s classification.</description>
        <time_frame>Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 46 out of 62 subjects in the ospemifene 30 mg group, 55 out of 69 subjects in the ospemifene 60 mg group, and 32 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Endometrial Biopsy</title>
          <description>Assessments were based on Blaustein’s classification.</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 46 out of 62 subjects in the ospemifene 30 mg group, 55 out of 69 subjects in the ospemifene 60 mg group, and 32 out of 49 subjects in the placebo group were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Atrophic/inactive/insufficient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weakly proliferative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atypical epithelial proliferation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proliferative pattern, disordered type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (Polyp, atrophic type)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperplasia or carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline in Serum Lipids</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Serum Lipids</title>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="14.807"/>
                    <measurement group_id="O2" value="2.35" spread="13.663"/>
                    <measurement group_id="O3" value="6.24" spread="12.904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low-density-lipoprotein cholesterol (LDL-C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="19.462"/>
                    <measurement group_id="O2" value="2.42" spread="19.107"/>
                    <measurement group_id="O3" value="10.38" spread="19.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-density-lipoprotein cholesterol (HDL-C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.48" spread="13.881"/>
                    <measurement group_id="O2" value="5.76" spread="12.686"/>
                    <measurement group_id="O3" value="2.39" spread="14.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="28.864"/>
                    <measurement group_id="O2" value="5.12" spread="31.076"/>
                    <measurement group_id="O3" value="20.36" spread="41.755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline in Serum Lipids</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Serum Lipids</title>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="13.910"/>
                    <measurement group_id="O2" value="-2.45" spread="12.323"/>
                    <measurement group_id="O3" value="-1.05" spread="9.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="19.748"/>
                    <measurement group_id="O2" value="-6.20" spread="18.623"/>
                    <measurement group_id="O3" value="-0.42" spread="15.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.07" spread="16.836"/>
                    <measurement group_id="O2" value="1.29" spread="12.787"/>
                    <measurement group_id="O3" value="-4.41" spread="14.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.10" spread="32.749"/>
                    <measurement group_id="O2" value="15.19" spread="35.789"/>
                    <measurement group_id="O3" value="21.57" spread="40.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Blood Chemistry Parameters</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Blood Chemistry Parameters</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine Aminotransferase (ALT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="9.39"/>
                    <measurement group_id="O2" value="-1.3" spread="8.73"/>
                    <measurement group_id="O3" value="-1.3" spread="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase (AST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="4.67"/>
                    <measurement group_id="O2" value="1.2" spread="5.43"/>
                    <measurement group_id="O3" value="0.5" spread="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase (CK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="50.97"/>
                    <measurement group_id="O2" value="-4.4" spread="48.78"/>
                    <measurement group_id="O3" value="18.7" spread="69.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Blood Chemistry Parameters</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Blood Chemistry Parameters</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="10.27"/>
                    <measurement group_id="O2" value="-3.2" spread="7.91"/>
                    <measurement group_id="O3" value="-2.2" spread="7.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="4.99"/>
                    <measurement group_id="O2" value="0.5" spread="5.03"/>
                    <measurement group_id="O3" value="0.3" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="62.70"/>
                    <measurement group_id="O2" value="1.2" spread="56.78"/>
                    <measurement group_id="O3" value="-6.0" spread="31.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Endometrial Safety With a Transvaginal Ultrasound (TVU)</title>
        <description>Mean change in endometrial thickness from baseline</description>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 50 out of 62 subjects in the ospemifene 30 mg group, 60 out of 69 subjects in the ospemifene 60 mg group, and 37 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Endometrial Safety With a Transvaginal Ultrasound (TVU)</title>
          <description>Mean change in endometrial thickness from baseline</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 50 out of 62 subjects in the ospemifene 30 mg group, 60 out of 69 subjects in the ospemifene 60 mg group, and 37 out of 49 subjects in the placebo group were analyzed.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.580" spread="1.9041"/>
                    <measurement group_id="O2" value="0.818" spread="1.6689"/>
                    <measurement group_id="O3" value="-0.119" spread="1.1629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Endometrial Safety With a TVU</title>
        <description>Mean change in endometrial thickness from baseline</description>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 46 out of 62 subjects in the ospemifene 30 mg group, 52 out of 69 subjects in the ospemifene 60 mg group, and 30 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Endometrial Safety With a TVU</title>
          <description>Mean change in endometrial thickness from baseline</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 46 out of 62 subjects in the ospemifene 30 mg group, 52 out of 69 subjects in the ospemifene 60 mg group, and 30 out of 49 subjects in the placebo group were analyzed.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.681" spread="2.5666"/>
                    <measurement group_id="O2" value="1.139" spread="1.5568"/>
                    <measurement group_id="O3" value="-0.041" spread="1.1455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Visual Evaluation of the Vagina</title>
        <description>Petechiae, pallor, friability, dryness in the mucosa, and redness in the mucosa were assessed on a 4-point scale (0=None, 1=Mild, 2=Moderate, 3=Severe).</description>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 65 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Evaluation of the Vagina</title>
          <description>Petechiae, pallor, friability, dryness in the mucosa, and redness in the mucosa were assessed on a 4-point scale (0=None, 1=Mild, 2=Moderate, 3=Severe).</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 65 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Petechiae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.94"/>
                    <measurement group_id="O2" value="-0.6" spread="0.82"/>
                    <measurement group_id="O3" value="-0.3" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pallor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.89"/>
                    <measurement group_id="O2" value="-1.2" spread="1.02"/>
                    <measurement group_id="O3" value="-0.5" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.02"/>
                    <measurement group_id="O2" value="-0.8" spread="0.95"/>
                    <measurement group_id="O3" value="-0.6" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal Dryness in Mucosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.07"/>
                    <measurement group_id="O2" value="-1.4" spread="0.91"/>
                    <measurement group_id="O3" value="-0.8" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal Redness in Mucosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.96"/>
                    <measurement group_id="O2" value="-0.7" spread="0.95"/>
                    <measurement group_id="O3" value="-0.4" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Visual Evaluation of the Vagina</title>
        <description>Petechiae, pallor, friability, dryness in the mucosa, and redness in the mucosa were assessed on a 4-point scale (0=None, 1=Mild, 2=Moderate, 3=Severe).</description>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Evaluation of the Vagina</title>
          <description>Petechiae, pallor, friability, dryness in the mucosa, and redness in the mucosa were assessed on a 4-point scale (0=None, 1=Mild, 2=Moderate, 3=Severe).</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Petechiae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.85"/>
                    <measurement group_id="O2" value="-0.7" spread="0.91"/>
                    <measurement group_id="O3" value="-0.4" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pallor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.74"/>
                    <measurement group_id="O2" value="-1.2" spread="1.15"/>
                    <measurement group_id="O3" value="-0.6" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.91"/>
                    <measurement group_id="O2" value="-0.7" spread="0.95"/>
                    <measurement group_id="O3" value="-0.5" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal Dryness in Mucosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.96"/>
                    <measurement group_id="O2" value="-1.4" spread="1.06"/>
                    <measurement group_id="O3" value="-1.1" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal Redness in Mucosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.96"/>
                    <measurement group_id="O2" value="-0.6" spread="1.03"/>
                    <measurement group_id="O3" value="-0.5" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Estradiol (E2) Levels</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estradiol (E2) Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="3.27"/>
                    <measurement group_id="O2" value="0.94" spread="5.97"/>
                    <measurement group_id="O3" value="0.15" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Luteinizing Hormone (LH) Levels</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Luteinizing Hormone (LH) Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.02" spread="5.26"/>
                    <measurement group_id="O2" value="-2.86" spread="6.97"/>
                    <measurement group_id="O3" value="-0.83" spread="4.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Follicle Stimulating Hormone (FSH) Levels</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Follicle Stimulating Hormone (FSH) Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.44" spread="11.78"/>
                    <measurement group_id="O2" value="-9.87" spread="14.00"/>
                    <measurement group_id="O3" value="-4.10" spread="11.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Sex Hormone Binding Globulin (SHBG) Levels</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sex Hormone Binding Globulin (SHBG) Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.71" spread="19.64"/>
                    <measurement group_id="O2" value="22.64" spread="28.07"/>
                    <measurement group_id="O3" value="-2.74" spread="12.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Testosterone (Total) Levels</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Testosterone (Total) Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="5.29"/>
                    <measurement group_id="O2" value="2.59" spread="5.75"/>
                    <measurement group_id="O3" value="-0.76" spread="7.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Testosterone (Free) Levels</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Testosterone (Free) Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.13"/>
                    <measurement group_id="O2" value="-0.00" spread="0.22"/>
                    <measurement group_id="O3" value="-0.03" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in E2 Levels</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in E2 Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="1.27"/>
                    <measurement group_id="O2" value="-0.02" spread="1.05"/>
                    <measurement group_id="O3" value="0.14" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in LH Levels</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LH Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.65" spread="6.73"/>
                    <measurement group_id="O2" value="-4.95" spread="7.59"/>
                    <measurement group_id="O3" value="-0.09" spread="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in FSH Levels</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FSH Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.39" spread="16.88"/>
                    <measurement group_id="O2" value="-15.60" spread="13.32"/>
                    <measurement group_id="O3" value="-6.29" spread="17.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in SHBG Levels</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SHBG Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.94" spread="20.81"/>
                    <measurement group_id="O2" value="28.09" spread="25.62"/>
                    <measurement group_id="O3" value="-5.94" spread="13.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Mammography</title>
        <description>Mammography was done for the detection of characteristic masses and microcalcifications in the breast.</description>
        <time_frame>Week 52 (Visit 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Mammography</title>
          <description>Mammography was done for the detection of characteristic masses and microcalcifications in the breast.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Breast cyst</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast microcalcification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mammogram abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Testosterone (Total) Levels</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Testosterone (Total) Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="5.13"/>
                    <measurement group_id="O2" value="3.48" spread="7.86"/>
                    <measurement group_id="O3" value="-0.95" spread="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Testosterone (Free) Levels</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Testosterone (Free) Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.10"/>
                    <measurement group_id="O2" value="-0.01" spread="0.15"/>
                    <measurement group_id="O3" value="0.01" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Antithrombin Antigen, P Levels</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Antithrombin Antigen, P Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="10.15"/>
                    <measurement group_id="O2" value="-2.4" spread="11.23"/>
                    <measurement group_id="O3" value="1.2" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Fibrinogen Levels</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fibrinogen Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.1" spread="83.18"/>
                    <measurement group_id="O2" value="-25.9" spread="63.17"/>
                    <measurement group_id="O3" value="12.1" spread="70.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Protein C Ag, P Levels</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Protein C Ag, P Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="20.20"/>
                    <measurement group_id="O2" value="-2.0" spread="20.68"/>
                    <measurement group_id="O3" value="14.2" spread="21.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Protein S Ag (Free), P Levels</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Protein S Ag (Free), P Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="13.33"/>
                    <measurement group_id="O2" value="6.8" spread="12.82"/>
                    <measurement group_id="O3" value="4.8" spread="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Thromboplastin Time</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Thromboplastin Time</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 63 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="7.48"/>
                    <measurement group_id="O2" value="-0.6" spread="3.37"/>
                    <measurement group_id="O3" value="0.3" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Antithrombin Antigen, P Levels</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Antithrombin Antigen, P Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="9.56"/>
                    <measurement group_id="O2" value="1.0" spread="9.28"/>
                    <measurement group_id="O3" value="7.1" spread="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Fibrinogen Levels</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fibrinogen Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.0" spread="61.79"/>
                    <measurement group_id="O2" value="-36.0" spread="67.82"/>
                    <measurement group_id="O3" value="7.4" spread="96.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Protein C Ag, P Levels</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Protein C Ag, P Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="17.11"/>
                    <measurement group_id="O2" value="-2.9" spread="19.20"/>
                    <measurement group_id="O3" value="10.6" spread="20.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Protein S Ag (Free), P Levels</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Protein S Ag (Free), P Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="16.77"/>
                    <measurement group_id="O2" value="11.1" spread="13.78"/>
                    <measurement group_id="O3" value="9.3" spread="15.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Thromboplastin Time</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Thromboplastin Time</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="4.13"/>
                    <measurement group_id="O2" value="0.5" spread="3.43"/>
                    <measurement group_id="O3" value="1.2" spread="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Breast Palpation</title>
        <description>Breast palpation was done by the investigator to assess abnormalities in the breast.</description>
        <time_frame>Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 65 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Breast Palpation</title>
          <description>Breast palpation was done by the investigator to assess abnormalities in the breast.</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 65 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Breast Palpation</title>
        <description>Breast palpation was done by the investigator to assess abnormalities in the breast.</description>
        <time_frame>Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Breast Palpation</title>
          <description>Breast palpation was done by the investigator to assess abnormalities in the breast.</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Hematology Tests</title>
        <description>Change from baseline</description>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 51 out of 62 subjects in the ospemifene 30 mg group, 61 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Hematology Tests</title>
          <description>Change from baseline</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 51 out of 62 subjects in the ospemifene 30 mg group, 61 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>(x10(9)/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes (WBC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" spread="1.2147"/>
                    <measurement group_id="O2" value="-0.211" spread="1.3608"/>
                    <measurement group_id="O3" value="0.207" spread="1.0489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" spread="0.0240"/>
                    <measurement group_id="O2" value="0.001" spread="0.0215"/>
                    <measurement group_id="O3" value="-0.005" spread="0.0186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.035" spread="0.3169"/>
                    <measurement group_id="O2" value="-0.064" spread="0.4004"/>
                    <measurement group_id="O3" value="0.116" spread="0.4972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" spread="0.1297"/>
                    <measurement group_id="O2" value="-0.042" spread="0.1127"/>
                    <measurement group_id="O3" value="0.009" spread="0.1362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" spread="0.9812"/>
                    <measurement group_id="O2" value="-0.094" spread="1.2380"/>
                    <measurement group_id="O3" value="0.083" spread="0.7953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" spread="0.0955"/>
                    <measurement group_id="O2" value="-0.009" spread="0.1072"/>
                    <measurement group_id="O3" value="0.002" spread="0.1168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="31.23"/>
                    <measurement group_id="O2" value="-5.6" spread="30.53"/>
                    <measurement group_id="O3" value="-4.5" spread="31.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Erythrocyte (RBC) Levels</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 51 out of 62 subjects in the ospemifene 30 mg group, 61 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Erythrocyte (RBC) Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 51 out of 62 subjects in the ospemifene 30 mg group, 61 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>(x10(12)/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.081" spread="0.2232"/>
                    <measurement group_id="O2" value="-0.089" spread="0.2500"/>
                    <measurement group_id="O3" value="0.026" spread="0.2240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemogobin Levels</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 51 out of 62 subjects in the ospemifene 30 mg group, 61 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemogobin Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 51 out of 62 subjects in the ospemifene 30 mg group, 61 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.150" spread="0.6664"/>
                    <measurement group_id="O2" value="-0.165" spread="0.6668"/>
                    <measurement group_id="O3" value="0.140" spread="0.6247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematocrit Levels</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 51 out of 62 subjects in the ospemifene 30 mg group, 61 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematocrit Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 51 out of 62 subjects in the ospemifene 30 mg group, 61 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.435" spread="2.0189"/>
                    <measurement group_id="O2" value="-0.529" spread="2.1667"/>
                    <measurement group_id="O3" value="0.398" spread="1.9951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Hematology Test Values</title>
        <description>Change from baseline</description>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Hematology Test Values</title>
          <description>Change from baseline</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>(x10(9)/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes (WBC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.061" spread="1.7480"/>
                    <measurement group_id="O2" value="-0.217" spread="0.9597"/>
                    <measurement group_id="O3" value="0.371" spread="1.3680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.0181"/>
                    <measurement group_id="O2" value="0.002" spread="0.0281"/>
                    <measurement group_id="O3" value="-0.003" spread="0.0214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.120" spread="0.4796"/>
                    <measurement group_id="O2" value="0.001" spread="0.3339"/>
                    <measurement group_id="O3" value="-0.028" spread="0.3352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.024" spread="0.1065"/>
                    <measurement group_id="O2" value="-0.028" spread="0.1017"/>
                    <measurement group_id="O3" value="0.021" spread="0.1216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.194" spread="1.7491"/>
                    <measurement group_id="O2" value="-0.258" spread="0.9189"/>
                    <measurement group_id="O3" value="0.377" spread="1.3568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="0.1029"/>
                    <measurement group_id="O2" value="-0.005" spread="0.0823"/>
                    <measurement group_id="O3" value="0.021" spread="0.1889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" spread="34.86"/>
                    <measurement group_id="O2" value="-16.4" spread="27.80"/>
                    <measurement group_id="O3" value="-11.3" spread="37.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Erythrocyte (RBC) Levels</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Erythrocyte (RBC) Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>(x10(12)/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.087" spread="0.2115"/>
                    <measurement group_id="O2" value="-0.155" spread="0.2113"/>
                    <measurement group_id="O3" value="0.028" spread="0.2350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin Levels</title>
        <time_frame>Baseine to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.141" spread="0.6261"/>
                    <measurement group_id="O2" value="-0.431" spread="0.6367"/>
                    <measurement group_id="O3" value="0.094" spread="0.6121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematocrit Levels</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematocrit Levels</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.445" spread="1.9207"/>
                    <measurement group_id="O2" value="-1.152" spread="1.9113"/>
                    <measurement group_id="O3" value="0.174" spread="2.0823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in pH of Urine</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 64 subjects in the ospemifene 30 mg group, 64 out of 69 subjects in the ospemifene 60 mg group, and 41 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in pH of Urine</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 64 subjects in the ospemifene 30 mg group, 64 out of 69 subjects in the ospemifene 60 mg group, and 41 out of 49 subjects in the placebo group were analyzed.</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.28"/>
                    <measurement group_id="O2" value="0.0" spread="0.97"/>
                    <measurement group_id="O3" value="0.1" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Specific Gravtiy of Urine</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 64 subjects in the ospemifene 30 mg group, 64 out of 69 subjects in the ospemifene 60 mg group, and 41 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Specific Gravtiy of Urine</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 64 subjects in the ospemifene 30 mg group, 64 out of 69 subjects in the ospemifene 60 mg group, and 41 out of 49 subjects in the placebo group were analyzed.</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.0074"/>
                    <measurement group_id="O2" value="-0.003" spread="0.0062"/>
                    <measurement group_id="O3" value="-0.000" spread="0.0065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in pH of Urine</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 57 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in pH of Urine</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 57 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.17"/>
                    <measurement group_id="O2" value="0.0" spread="1.15"/>
                    <measurement group_id="O3" value="0.2" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Specific Gravity of Urine</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 57 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Specific Gravity of Urine</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 57 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" spread="0.0061"/>
                    <measurement group_id="O2" value="-0.002" spread="0.0074"/>
                    <measurement group_id="O3" value="-0.001" spread="0.0067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP)</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 66 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP)</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 66 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="15.33"/>
                    <measurement group_id="O2" value="2.4" spread="12.16"/>
                    <measurement group_id="O3" value="0.5" spread="11.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Diastolic Blood Pressure (DBP)</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 66 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure (DBP)</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 66 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="9.49"/>
                    <measurement group_id="O2" value="0.5" spread="8.29"/>
                    <measurement group_id="O3" value="0.3" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pulse Rate</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 66 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 66 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="11.71"/>
                    <measurement group_id="O2" value="0.8" spread="10.61"/>
                    <measurement group_id="O3" value="2.2" spread="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weight</title>
        <time_frame>Baseline to Week 26 (Visit 5)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 66 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 66 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="3.902"/>
                    <measurement group_id="O2" value="0.66" spread="2.997"/>
                    <measurement group_id="O3" value="0.78" spread="2.732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in BMI</title>
        <time_frame>Baseline to Week 26</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 66 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BMI</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 26, 52 out of 62 subjects in the ospemifene 30 mg group, 66 out of 69 subjects in the ospemifene 60 mg group, and 42 out of 49 subjects in the placebo group were analyzed.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.331" spread="1.4659"/>
                    <measurement group_id="O2" value="0.253" spread="1.1244"/>
                    <measurement group_id="O3" value="0.293" spread="1.0131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in SBP</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SBP</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="15.28"/>
                    <measurement group_id="O2" value="0.9" spread="15.30"/>
                    <measurement group_id="O3" value="4.2" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DBP</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DBP</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="10.32"/>
                    <measurement group_id="O2" value="0.7" spread="9.97"/>
                    <measurement group_id="O3" value="0.8" spread="7.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pulse Rate</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="9.78"/>
                    <measurement group_id="O2" value="-0.5" spread="12.05"/>
                    <measurement group_id="O3" value="2.9" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weight</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.99" spread="4.975"/>
                    <measurement group_id="O2" value="0.98" spread="3.055"/>
                    <measurement group_id="O3" value="1.99" spread="3.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in BMI</title>
        <time_frame>Baseline to Week 52 (Visit 6)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ospemifene 30 mg (Dose 1)</title>
            <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ospemifene 60 mg (Dose 2)</title>
            <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BMI</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at Week 52, 49 out of 62 subjects in the ospemifene 30 mg group, 58 out of 69 subjects in the ospemifene 60 mg group, and 35 out of 49 subjects in the placebo group were analyzed.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.379" spread="1.8594"/>
                    <measurement group_id="O2" value="0.376" spread="1.1942"/>
                    <measurement group_id="O3" value="0.748" spread="1.1672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>40 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ospemifene 30 mg (Dose 1)</title>
          <description>Subjects took a daily oral dose of one 30 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
        </group>
        <group group_id="E2">
          <title>Ospemifene 60 mg (Dose 2)</title>
          <description>Subjects took a daily oral dose of one 60 mg ospemifene film-coated tablet each morning with food for 40 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Subjects took a daily oral dose of one placebo tablet (identical in appearance to ospemifene tablets) each morning with food for 40 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Encephalitis Herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Meningitis Candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer In Situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Breast Prosthesis Implantation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shionogi Clinical Trials Administrator</name_or_title>
      <organization>Shionogi Inc.</organization>
      <phone>800-849-9707</phone>
      <email>Shionogiclintrials-admin@shionogi.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

